SellYourAIData
Get a free valuation Contact

AI Data Deal TrackerDeal brief

×

23andMe signs $20M one-year data license with GSK

23andMe announced a collaboration extension with GSK that includes a new one-year, non-exclusive data license. 23andMe received $20 million upfront for access to de-identified, summary-level results from analyses of its genetic database.

SUNNYVALE, October 30, 2023 23andMe announced a collaboration extension with GSK that includes a new data licensing agreement. Under an amendment to the existing Collaboration Agreement, 23andMe receives a $20 million upfront payment for a one-year, non-exclusive data license.1

Terms of the deal

The license runs for 12 months. GSK receives access to de-identified, summary-level results from genome-wide and phenome-wide analyses of the 23andMe database, and 23andMe also provides research services for analyses of that data during the same period.1

Any new drug discovery programs that GSK initiates during the agreement will be owned and advanced solely by GSK. 23andMe may be eligible for downstream royalties under certain uses of the database by GSK.1 For three previously initiated programs, 23andMe has taken a royalty option, and both companies keep royalties on several active programs from the original collaboration.1

What it means for data sellers

The deal shows that genetic and health datasets can be licensed in aggregate form for a fixed fee and a short term. The buyer here received summary results and services, not individual-level records. This entry describes a drug-discovery data license, not an AI-training license.

This entry is a news summary. SellYourAIData was not involved in the deal.

How the deal came together

  1. An existing collaboration is amended. On October 30, 2023 23andMe announced an amendment to its Collaboration Agreement with GSK that adds a new data licensing agreement.
  2. GSK pays upfront for a 12-month license. 23andMe receives a $20 million upfront payment for a non-exclusive data license that runs 12 months.
  3. What GSK receives. GSK gets de-identified, summary-level results from genome-wide and phenome-wide analyses of the 23andMe database, plus research services for analyses over the same period.
  4. Ownership and royalties. Any new drug discovery programs GSK starts during the agreement belong solely to GSK, and 23andMe may earn downstream royalties on certain uses of the database.

Takeaways for companies with data

  • A data owner can license summary-level results without handing over raw records, which limits privacy exposure while still earning a large upfront fee.
  • Short, non-exclusive terms let the seller keep selling the same asset to other buyers.
  • Royalty rights on downstream programs can be negotiated on top of an upfront data fee.

Sources

Every numbered reference above points to an entry here. Figures come from these pages as of the date shown at the top of the article. Where a source reports a number it got from unnamed people, the text says so.

  1. 23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK (BioSpace, October 2023)

###

About the AI Data Deal Tracker

SellYourAIData tracks publicly reported sales and licenses of data to AI companies, with the price, terms and sources for each. Entries are checked against public reporting and updated as deals change. SellYourAIData was not involved in this deal. To ask what your company's data could sell for, get a free valuation. To report a deal, contact us.